LENZ Therapeutics (LENZ) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neumora Therapeutics (NMRA) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 75.3% versus a loss of 92.7%. LENZ Therapeutics is the larger company by market cap ($110.3 million vs $94.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LENZ | NMRA |
|---|---|---|
| Share price | $3.51 | $0.503 |
| Market cap | $110.29M | $94.51M |
| 1-day change | -0.57% | +4.85% |
| YTD return | -77.94% | -73.20% |
| 1-year return | -92.74% | -75.27% |
| 5-year return | -96.05% | — |
| EPS (TTM) | $-4.13 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.75 | $3.65 |
| 52-week low | $3.35 | $0.45 |
| Distance from 52-week high | -92.49% | -86.22% |
| Analyst consensus | none | none |
| Avg. price target upside | +583.76% | +1120.68% |
| Average volume | 833.64K | 1.19M |
| Shares outstanding | 31.42M | 187.90M |
| Employees | 152 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NMRA has outperformed LENZ by 17.5 percentage points over the past year.
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 152 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
LENZ vs NMRA FAQ
Which is bigger, LENZ Therapeutics or Neumora Therapeutics?
LENZ Therapeutics (LENZ) is larger, with a market capitalization of $110.29M compared with $94.51M for Neumora Therapeutics (NMRA).
Which stock has performed better over the past year, LENZ or NMRA?
NMRA returned -75.27% over the past 12 months, compared with -92.74% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are LENZ Therapeutics and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.